Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001214396 | SCV001386077 | uncertain significance | Severe X-linked myotubular myopathy | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine with valine at codon 59 of the MTM1 protein (p.Ile59Val). The isoleucine residue is weakly conserved and there is a small physicochemical difference between isoleucine and valine. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the ExAC database. This variant has not been reported in the literature in individuals affected with MTM1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV003490125 | SCV004236396 | uncertain significance | not provided | 2023-06-21 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001214396 | SCV002084506 | uncertain significance | Severe X-linked myotubular myopathy | 2021-07-23 | no assertion criteria provided | clinical testing |